文献速递肾移植血液净化与透析

Medicare ESRD治疗选择模型与肾移植及时可及性的关联

Association of Medicare's ESRD Treatment Choices Model with Timely Access to Kidney Transplantation in the Southeastern United States.
PubMed 文献 · J Am Soc Nephrol · 2026-10-28

该研究评估Medicare的ESRD治疗选择(ETC)模型是否影响透析机构可控的移植可及步骤。采用双重差分分析比较ETC与非ETC机构中成人透析患者的转诊、评估、等待名单及活体移植。结果显示ETC实施与及时转诊、评估启动和等待名单/活体移植的差异变化均无统计学显著性,提示仅靠激励错位难以解释ETC对移植的有限影响。

要点

  • ETC实施与及时转诊的差异变化为3.58个百分点(95%CI -1.30至8.45),无统计学显著性。
  • 评估启动的差异变化为8.52个百分点(95%CI -1.42至18.45),无统计学显著性。
  • 等待名单或活体移植的差异变化为3.61个百分点(95%CI -0.26至7.48),无统计学显著性。

核心结论

  • ETC实施未与及时移植转诊、评估启动、等待名单或活体移植的统计学显著改善相关。

研究设计与样本

  • 基于美国肾脏数据系统、早期移植可及登记和移植受者科学登记链接数据的双重差分分析。
  • 纳入乔治亚、北卡、南卡在2015-2019和2021-2023启动透析的成人Traditional Medicare受益者,共26809人、706家机构。
  • 比较ETC机构与对照机构在转诊、评估、等待名单和活体移植等结局的差异变化。

主要发现

  • 及时转诊的调整差异变化为3.58个百分点(95%CI -1.30至8.45)。
  • 评估启动的调整差异变化为8.52个百分点(95%CI -1.42至18.45)。
  • 等待名单或活体移植的调整差异变化为3.61个百分点(95%CI -0.26至7.48)。
  • 时间事件分析与主要结果一致,且两地区均存在COVID时代移植转诊的显著延迟。

临床怎么用

  • 不能仅依赖财务激励来改善透析机构可控的移植转诊和评估流程。
  • 需关注COVID时代移植转诊延迟对可及性的持续影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2021, Medicare's End-Stage Renal Disease Treatment Choices (ETC) Model randomly assigned 30% of U.S. dialysis facilities to financial incentives to increase home dialysis, waitlisting, and living-donor kidney transplantation. Early evaluations found no improvements in waitlisting or transplantation, but whether the ETC influenced upstream transplant access steps controlled by dialysis facilities remains unknown. METHODS: Using linked data from the United States Renal Data System, Early Steps to Transplant Access Registry, and Scientific Registry of Transplant Recipients, we assessed the association of ETC implementation with transplant referral within 1 year of dialysis initiation, evaluation initiation within 6 months of referral, waitlisting or living-donor transplantation within 2 years of dialysis initiation, and corresponding time-to-event outcomes. Difference-in-differences analyses compared outcomes at ETC versus control facilities among adult Traditional Medicare beneficiaries initiating dialysis in Georgia, North Carolina, and South Carolina before (2015-2019) and after (2021-2023) ETC implementation. Follow-up extended through December 2024 (referral, evaluation) and June 2025 (waitlisting, transplantation). RESULTS: Among 26,809 individuals in 706 facilities (mean [SD] age, 57 [13]; 43% female; 53% non-Hispanic Black; 46% dual Medicare/Medicaid eligible), ETC implementation was associated with adjusted differential increases in timely referral, evaluation start, and waitlisting or living-donor transplantation of 3.58 (95% CI, -1.30 to 8.45), 8.52 (95% CI, -1.42 to 18.45), and 3.61 (95% CI, -0.26 to 7.48) percentage points, respectively, relative to control facilities. Time-to-event analyses were consistent with primary results and substantial COVID-era delays in transplant referral across both ETC and control regions. CONCLUSIONS: ETC implementation was not associated with definitive evidence of statistically significant improvements in timely transplant referral, evaluation initiation, waitlisting, or living-donor transplantation in the Southeastern U.S. The absence of detectable changes in transplant access processes directly influenced by dialysis facilities suggests that incentive misalignment alone is unlikely to explain the ETC Model's limited impact on transplantation.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Drewry KM, Huffman KM, Kim D, et al. Association of Medicare's ESRD Treatment Choices Model with Timely Access to Kidney Transplantation in the Southeastern United States. J Am Soc Nephrol. 2026. PMID: 42949789. doi:10.1681/ASN.0000001300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。